Two-year event rates per 100 person–years in the GARFIELD-AF UK population by treatment at baseline
| Treatment at baseline | All-cause mortality | Non-haemorrhagic stroke/systemic embolism | Major bleeding | |||
|---|---|---|---|---|---|---|
| Events | Rate (95% CI) | Events | Rate (95% CI) | Events | Rate (95% CI) | |
| OAC | 172 | 3.89 (3.35 to 4.52) | 46 | 1.05 (0.79 to 1.40) | 55 | 1.26 (0.97 to 1.64) |
| No OAC | 106 | 4.68 (3.87 to 5.66) | 49 | 2.21 (1.67 to 2.92) | 25 | 1.11 (0.75 to 1.65) |
| DOAC | 52 | 3.98 (3.03 to 5.23) | 13 | 1.00 (0.58 to 1.73) | 10 | 0.77 (0.41 to 1.43) |
| VKA | 120 | 3.85 (3.22 to 4.61) | 33 | 1.07 (0.76 to 1.51) | 45 | 1.46 (1.09 to 1.96) |
| OAC + antiplatelet | 37 | 4.43 (3.21 to 6.11) | 6 | 0.72 (0.32 to 1.61) | 15 | 1.82 (1.10 to 3.02) |
| OAC only | 135 | 3.77 (3.18 to 4.46) | 40 | 1.13 (0.83 to 1.54) | 40 | 1.13 (0.83 to 1.54) |
| Antiplatelet only | 60 | 4.35 (3.37 to 5.60) | 35 | 2.61 (1.87 to 3.63) | 16 | 1.17 (0.72 to 1.91) |
| No OAC nor antiplatelet | 46 | 5.19 (3.89 to 6.93) | 14 | 1.60 (0.95 to 2.70) | 9 | 1.02 (0.53 to 1.97) |
DOAC = direct-acting oral anticoagulant. GARFIELD-AF = Global Anticoagulant in the FIELD — Atrial Fibrillation registry. OAC = oral anticoagulant. VKA = vitamin K antagonist.